Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $64.88, for a total value of $25,952.00. Following the transaction, the vice president directly owned 78,945 shares of the company's stock, valued at $5,121,951.60. The trade was a 0.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Friday, June 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $61.37, for a total value of $24,548.00.

ANI Pharmaceuticals Trading Up 2.2%

ANIP stock traded up $1.44 during midday trading on Thursday, hitting $68.04. 401,195 shares of the company's stock were exchanged, compared to its average volume of 319,161. The business has a 50-day simple moving average of $62.88 and a two-hundred day simple moving average of $62.58. The company has a current ratio of 2.66, a quick ratio of 1.98 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $1.47 billion, a PE ratio of -53.57 and a beta of 0.57. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The company had revenue of $197.12 million during the quarter, compared to analysts' expectations of $179.75 million. During the same quarter last year, the firm earned $0.82 earnings per share. The firm's quarterly revenue was up 43.4% compared to the same quarter last year. On average, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. boosted its position in shares of ANI Pharmaceuticals by 68.3% during the first quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company's stock worth $10,565,000 after buying an additional 64,021 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of ANI Pharmaceuticals by 14.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company's stock worth $854,000 after buying an additional 1,972 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of ANI Pharmaceuticals by 53.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company's stock worth $599,000 after buying an additional 3,112 shares during the period. GAMMA Investing LLC boosted its position in shares of ANI Pharmaceuticals by 163.8% during the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after buying an additional 881 shares during the period. Finally, Victory Capital Management Inc. boosted its position in shares of ANI Pharmaceuticals by 6.6% during the fourth quarter. Victory Capital Management Inc. now owns 13,777 shares of the specialty pharmaceutical company's stock worth $762,000 after buying an additional 858 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ANIP has been the subject of several recent research reports. Truist Financial increased their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a report on Monday, April 21st. Wall Street Zen cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. HC Wainwright initiated coverage on ANI Pharmaceuticals in a report on Thursday, July 10th. They issued a "buy" rating and a $84.00 price target for the company. Finally, Guggenheim reaffirmed a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $78.88.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.